Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Hyperlipidemia and atherosclerosis lead to cardiovascular diseases and are an indirect cause
of increased death rate in the general population. This association is still more evident in
specific subpopulations, like patients with advanced chronic kidney disease (CKD), especially
hemodialysis (HD) patients, due to a higher prevalence of lipid disturbances and
atherosclerosis compared to the general population. Cardiovascular events in CKD patients are
frequently associated with traditional risk factors, including diabetes, male sex,
hypertension, dyslipidemia and advanced age. However, these factors failed to fully account
for the increased risk of cardiovascular events in CKD. The efforts are made to identify new
risk factors that contribute to the development of atherosclerosis and participate in causes
of cardiovascular death. In 2003, there were identified peptides designated salusin-alpha and
salusin-beta. Development of atherosclerosis may be suppressed by salusin-alpha.
Salusin-alpha may have a lipid lowering effect, similar to that of statins.
The purpose of this study is to investigate whether 1) salusin-alpha is associated with lipid
metabolism of HD patients (without or with metabolic syndrome or type 2 diabetes mellitus),
similarly or not like in healthy or obese subjects; 2) treatment with atorvastatin and its
effects are associated with changes in plasma salusin-alpha concentration, if so - whether it
is dependent on the direct influence of atorvastatin on salusin-alpha or associated with a
decrease in serum lipid level; 3) salusin-alpha may predict mortality in HD patients.